Latest Breaking News On - Single agent - Page 1 : comparemela.com

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program

United statesPrnewswire johnsonNatashab leighlNone of janssen research developmentJanssen research developmentJanssen biotech incPrincess margaret cancer centreAmerican society of clinical oncologyExchange commissionEuropean medicines agencyClinical oncologyAnnual meetingBiologics license applicationNew drug applicationPriority reviewPractice guidelines

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNatashab leighlPrnewswire johnsonJanssen biotech incNone of janssen research developmentAmerican society of clinical oncology annual meetingEuropean medicines agencyAmerican lung associationNational cancer instituteWorld health organizationAmerican cancer societyAmerican society of clinical oncologyJanssen research developmentNational comprehensive cancer network incExchange commissionPrincess margaret cancer centre

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesGursel aktanData monitoring committeeDrug administrationStatement of merck co incEuropean network for gynecologic oncology trialMerck research laboratoriesFoundation incExchange commissionMerck co incMerck researchBiologics license applicationPrescription drug user fee actEuropean networkGynecologic oncology trialAmong merck

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication .

United statesMerck research laboratoriesDrug administrationMerck co incEuropean society for medical oncologyStatement of merck co incExchange commissionMarjorie greenMerck researchEuropean societyMedical oncologyImportant safety informationSelected important safetyFatal immune mediated adverseSingle agentThyroid disorders

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSuperkine immunotherapiesChristina cameronMerck co incMedicenna therapeutics corpMerck sharp dohmePresents updated resultsSingle agentDose escalationOngoing dose expansionAmerican associationCancer researchFahar merchantChief executive officerRecommended dose